Department of Clinical Pharmacy and Pharmaceutical Management, School of Pharmacy, Fudan University, Shanghai, China; Sino-Dannish Regulatory Science Center, Fudan University, Shanghai, China.
Department of Clinical Pharmacy and Pharmaceutical Management, School of Pharmacy, Fudan University, Shanghai, China.
Pharmacol Res. 2019 Oct;148:104412. doi: 10.1016/j.phrs.2019.104412. Epub 2019 Sep 3.
In China, child and adolescent pediatricians often face challenges in treating children with the appropriate medications. Within the last 8 years, the Chinese government has already initiated a series of policies to promote development of age-appropriate medicines for children. In this study,we introduced the current status of pediatric drugs, obstacles for pediatric drugs development and regulatory reforms in China. The lack of label information in drugs for children, inadequacy of age-appropriate dosage forms and strengths, and shortage of pediatric drugs are some of the problems commonly faced. There exists neither mandatory requirements nor enough financial drivers for development of pediatric medicines. Though some progress in terms of pediatric drugs development as well as distribution have been made by Chinese government over past years, further efforts are necessary to improve availability of pediatric medications.
在中国,儿科医生在为儿童提供适当药物治疗方面经常面临挑战。在过去的 8 年中,中国政府已经出台了一系列政策,以促进儿童专用药物的发展。在这项研究中,我们介绍了中国儿科药物的现状、儿科药物开发的障碍以及监管改革。儿童用药缺乏标签信息、儿童适宜剂型和规格不足以及儿童用药短缺是常见的问题。既没有强制性要求,也没有足够的财政激励来开发儿科药物。尽管中国政府在过去几年中在儿科药物开发和分销方面取得了一些进展,但仍需进一步努力改善儿科药物的可获得性。